NCT02065375View on ClinicalTrials.gov

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

PHASE2CompletedINTERVENTIONAL

Enrollment

109

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Inflammation and Pain Following Ocular Surgery

Interventions

DRUG

Omaveloxolone Ophthalmic Suspension 1.0%

DRUG

Omaveloxolone Opthalmic Suspension 0.5%

DRUG

Placebo

Trial Locations (6)

27909

Elizabeth City

33907

Fort Myers

64133

Kansas City

75022

Houston

78731

Austin

92843

Garden Grove

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

AbbVie

INDUSTRY

lead

Biogen

INDUSTRY